Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2003
03/13/2003US20030050224 Treatment of glial tumors with glutamate antagonists
03/13/2003US20030049843 Gene delivery vectors with cell type specificity for mesenchymal stem cells
03/13/2003US20030049838 Generation of neuronal cell for use in the treatment of nervous system disorders; prepare nutrient broth contain nerve growth factor, inoculate with cells, propagate and monitor cells
03/13/2003US20030049797 Hybrid proteins for autoimmune disease
03/13/2003US20030049790 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof
03/13/2003US20030049732 Apoptosis related polynucleotides, polypeptides, and antibodies
03/13/2003US20030049728 Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
03/13/2003US20030049706 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of bacterial infections
03/13/2003US20030049672 Modulation of protein binding; obtain sample containing polypeptides, incubate with modulator, detect adjustment in protein activity
03/13/2003US20030049643 G protein-coupled receptors for use in the treatment of cardiovascular, nervous system, angina pectoris, inflamatory bowel, allergies and gastrointestinal disorders
03/13/2003US20030049340 Use of a preparation of cimicifuga racemosa
03/13/2003US20030049308 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication
03/13/2003US20030049264 Releasing neurotransmitters; analgesics
03/13/2003US20030049260 Method of improving cognitive function
03/13/2003US20030049255 Interleukin-1 receptors in the treatment of diseases
03/13/2003US20030049248 Netrins
03/13/2003US20030049245 Methods for sterilizing preparations of digestive enzymes
03/13/2003US20030049208 For delivering a medicant; product includes a coating having a medicament or agent; bioavailabilty; chewing gum product that releases caffiene for improved performance
03/13/2003CA2483959A1 Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons
03/13/2003CA2459937A1 Ncam binding compounds
03/13/2003CA2459161A1 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003CA2459146A1 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
03/13/2003CA2459136A1 A caspase-8 binding protein, its preparation and use
03/13/2003CA2459045A1 Antidiabetic extracts of artemisia dracunculus
03/13/2003CA2458968A1 Method for classification of anti-psychotic drugs
03/13/2003CA2458876A1 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
03/13/2003CA2458799A1 Treatment for central nervous system disorders
03/13/2003CA2458348A1 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
03/13/2003CA2458213A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
03/13/2003CA2457922A1 Novel pyrazole analogs acting on cannabinoid receptors
03/13/2003CA2457861A1 Piperidine derivatives useful as ccr5 antagonists
03/13/2003CA2457534A1 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
03/13/2003CA2455896A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
03/12/2003WO2002022569A1 Method for producing chiral compounds
03/12/2003WO2002022568A1 ss-THIO-AMINO ACIDS
03/12/2003EP1291430A1 Ceramide kinase and dna encoding the same
03/12/2003EP1291360A1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
03/12/2003EP1291358A1 Feline hepatocyte growth factor
03/12/2003EP1291346A1 Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
03/12/2003EP1291345A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
03/12/2003EP1291022A1 Methods of using lanreotide, a somatostatin analogue
03/12/2003EP1291021A2 Pharmaceutical formulations for thyroid hormones
03/12/2003EP1290451A2 Diagnosis of alzheimer's disease using ldl receptor protein-1
03/12/2003EP1290227A1 Compositions, kits, and methods for identification and modulation of type i diabetes
03/12/2003EP1290193A2 Protein phosphatases
03/12/2003EP1290187A2 Humain kinases
03/12/2003EP1290180A2 Drug metabolizing enzymes
03/12/2003EP1290174A2 G-protein coupled receptor org3.
03/12/2003EP1290169A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
03/12/2003EP1290167A1 Human kcnq5 potassium channel, methods and compositions thereof
03/12/2003EP1290166A1 Mutation in the beta 2 nicotinic acetylcholine receptor subunit associated with nocturnal frontal lobe epilepsy
03/12/2003EP1290163A2 Regulation of human serotonin-like g protein-coupled receptor
03/12/2003EP1290143A2 Method to determine the differentiation potential of a target cell
03/12/2003EP1290033A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
03/12/2003EP1290026A2 Human sez6 nucleic acids and polypeptides
03/12/2003EP1290025A2 REGULATION OF HUMAN GluR5-LIKE RECEPTOR
03/12/2003EP1289997A1 Macrolides
03/12/2003EP1289996A1 Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
03/12/2003EP1289993A1 Caspase inhibitors and uses thereof
03/12/2003EP1289992A1 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
03/12/2003EP1289988A1 1,4-diazabicyclo 3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
03/12/2003EP1289987A1 4-(2-phenylthiazol-5-yl)-1,4-diazabicyclo- 3.2.2]nonane derivatives, preparation and therapeutic use thereof
03/12/2003EP1289986A1 1,4-diazabicyclo 3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
03/12/2003EP1289980A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
03/12/2003EP1289966A1 SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
03/12/2003EP1289961A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
03/12/2003EP1289957A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
03/12/2003EP1289956A1 Chemical compounds
03/12/2003EP1289955A1 Piperidines for use as orexin receptor antagonists
03/12/2003EP1289944A2 Thioketals and thioethers for inhibiting the expression of vcam-1
03/12/2003EP1289940A2 Excitatory amino acid receptor modulators
03/12/2003EP1289935A1 Excitatory amino acid receptor modulators
03/12/2003EP1289561A2 Ligand conjugates and methods for preparing same
03/12/2003EP1289559A1 Combinations of enzyme inhibitor-containing preparations and the use thereof
03/12/2003EP1289558A2 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
03/12/2003EP1289553A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
03/12/2003EP1289544A2 Method for treating a movement disorder
03/12/2003EP1289543A2 Formulations and methods for treating hypercoagulable states
03/12/2003EP1289541A2 Interferon for the treatment of multiple sclerosis
03/12/2003EP1289540A2 Methods and compositions for producing a neurosalutary effect in a subject
03/12/2003EP1289536A2 Apoptotic entities for use in treatment of endothelium dysfunction disorders
03/12/2003EP1289535A2 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
03/12/2003EP1289534A2 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
03/12/2003EP1289529A1 Active substance combination containing a compound with an opioid effect and at least one further compound of formula i
03/12/2003EP1289528A1 Active substance combination containing an opioid having a fentanyl-type structure and ketamine
03/12/2003EP1289527A2 Use of (+)-alpha -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
03/12/2003EP1289523A1 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
03/12/2003EP1289522A2 Medicaments for treating dementia
03/12/2003EP1289521A2 Combination of lipoic acid and c 1 donors for the treatment of disorders of the central nervous system
03/12/2003EP1289520A2 Pharmaceutical compositions for the treatment of depression comprising famotidine
03/12/2003EP1289517A2 Pharmaceutical compositions comprising cannabidiol derivatives
03/12/2003EP1289516A1 Composition for pain mediation and apparatus and method of use thereof
03/12/2003EP1289514A1 Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
03/12/2003EP1289512A2 Agents and methods for increasing brain chaperonin levels
03/12/2003EP1289507A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
03/12/2003EP1289504A2 Neurotoxin implant
03/12/2003EP1289503A2 O/w emulsion
03/12/2003EP1181018B1 Ziprasidone suspension
03/12/2003EP1135121B1 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
03/12/2003EP1133290B1 Use of inhibitors of acetylcholinesterase for the treatment of deliriums
1 ... 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 ... 1833